Erratum: Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L costimulation blockade (Transplantation (July 27, 2005) 80 (255-263) DOI: 10.1097/01.TP.0000165429.57421.D6);Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade

Transplantation

Volumn 80, Issue 2, 2005, Pages 255-263

  Guillonneau, Carole ^a   Aubry, Venceslas ^a   Renaudin, Karine ^b   Séveno, Céline ^a   Usal, Claire ^a   Tezuka, Katsunari ^c   Anegon, Ignacio ^a,b  

^a INSERM   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c Research Laboratory   (Japan)

Author keywords

Co stimulation; Gene therapy; Tolerance; Transplantation

Indexed keywords

ADENOVIRUS VECTOR; ALLOANTIBODY; CD16 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ICOS LIGAND; ICOS PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CD40IG PROTEIN, RECOMBINANT; HYBRID PROTEIN; INDUCIBLE T CELL CO STIMULATOR; INDUCIBLE T-CELL CO-STIMULATOR; T LYMPHOCYTE ANTIGEN;

ACUTE GRAFT REJECTION; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; CARDIAC GRAFT REJECTION; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TRANSFER; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNE RESPONSE; IMMUNOHISTOLOGY; IMMUNOLOGICAL TOLERANCE; MALE; MIXED LYMPHOCYTE REACTION; NONHUMAN; PRIORITY JOURNAL; RAT; VIRAL GENE THERAPY; VIRUS RECOMBINANT; ALLOTRANSPLANTATION; ANIMAL; CHRONIC DISEASE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; GRAFT REJECTION; IMMUNOLOGY; LEWIS RAT; LYMPHOCYTE ACTIVATION; T LYMPHOCYTE; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CD40 LIGAND; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MALE; RATS; RATS, INBRED LEW; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 23044471742     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200508270-00029     Document Type: Erratum

References (39)

1. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970; 169(950): 1042.
2. Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975; 53(1): 27.
3. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248(4961): 1349.
4. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991.
5. Shirasugi N, Adams AB, Durham MM, et al. Prevention of chronic rejection in murine cardiac allografts: A comparison of chimerism- and nonchimerism-inducing costimulation blockade-based tolerance induction regimens. J Immunol 2002; 169(5): 2677.
6. Shimizu K, Schonbeck U, Mach F, et al. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J Immunol 2000; 165(6): 3506.
7. Guillot C, Guillonneau C, Mathieu P, et al. Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection. J Immunol 2002; 168(4): 1600.
8. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381(6581): 434.
9. Liang L, Sha WC. The right place at the right time: Novel B7 family members regulate effector T cell responses. Curr Opin Immunol 2002; 14(3): 384.
10. Greenwald RJ, Latchman YE, Sharpe AH. Negative co-receptors on lymphocytes. Curr Opin Immunol 2002; 14(3): 391.
11. Adams AB, Larsen CP, Pearson TC, et al. The role of TNF receptor and TNF superfamily molecules in organ transplantation. Am J Transplant 2002; 2(1): 12.
12. Guillonneau C, Louvet C, Renaudin K, et al. The role of TNF-related activation-induced cytokine-receptor activating NF-kappa B interaction in acute allograft rejection and CD40L-independent chronic allograft rejection. J Immunol 2004; 172(3): 1619.
13. Ozkaynak E, Wang L, Goodearl A, et al. Programmed death-1 targeting can promote allograft survival. J Immunol 2002; 169(11): 6546.
14. Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397(6716): 263.
15. Yoshinaga SK, Whoriskey JS, Khare SD, et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999; 402(6763): 827.
16. Coyle AJ, Lehar S, Lloyd C, et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 2000; 13(1): 95.
17. Tezuka K, Tsuji T, Hirano D, et al. Identification and characterization of rat AILIM/ICOS, a novel T-cell costimulatory molecule, related to the CD28/CTLA4 family. Biochem Biophys Res Commun 2000; 276(1): 335.
18. London CA, Lodge MP, Abbas AK. Functional responses and costimulator dependence of memory CD4+ T cells. J Immunol 2000; 164(1): 265.
19. Dong C, Nurieva RI. Regulation of immune and autoimmune responses by ICOS. J Autoimmun 2003; 21(3): 255.
20. Gonzalo JA, Tian J, Delaney T, et al. ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nat Immunol 2001; 2(7): 597.
21. Ozkaynak E, Gao W, Shemmeri N, et al. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol 2001; 2(7): 591.
22. Guo L, Fujino M, Kimura H, et al. Simultaneous blockade of co-stimulatory signals, CD28 and ICOS, induced a stable tolerance in rat heart transplantation. Transpl Immunol 2003; 12(1): 41.
23. Salama AD, Yuan X, Nayer A, et al. Interaction between ICOS-B7RP1 and B7-CD28 costimulatory pathways in alloimmune responses in vivo. Am J Transplant 2003; 3(4): 390.
24. Kosuge H, Suzuki J, Gotoh R, et al. Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway. Transplantation 2003; 75(8): 1374.
25. Harada H, Salama AD, Sho M, et al. The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest 2003; 112(2): 234.
26. Guo L, Li XK, Funeshima N, et al. Prolonged survival in rat liver transplantation with mouse monoclonal antibody against an inducible co-stimulator (ICOS). Transplantation 2002; 73(7): 1027.
27. David A, Coupel-Clauce H, Chetritt J, et al. Anti-adenovirus immune responses in rats are enhanced by interleukin 4 but not interleukin 10 produced by recombinant adenovirus. Hum Gene Ther 1998; 9(12): 1755.
28. Guillot C, Mathieu P, Coathalem H, et al. Tolerance to cardiac allografts via local and systemic mechanisms after adenovirus-mediated CTLA4Ig expression. J Immunol 2000; 164( 10): 5258.
29. McWhinnie DL, Thompson JF, Taylor HM, et al. Morphometric analysis of cellular infiltration assessed by monoclonal antibody labeling in sequential human renal allograft biopsies. Transplantation 1986; 42(4): 352.
30. Gracie JA, Bradley JA. Interleukin-12 induces interferon-gamma-dependent switching of IgG alloantibody subclass. Eur J Immunol 1996; 26(6): 1217.
31. Akbari O, Freeman GJ, Meyer EH, et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med 2002; 8(9): 1024.
32. Lohning M, Hutloff A, Kallinich T, et al. Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J Exp Med 2003; 197(2): 181.
33. Okamoto N, Tezuka K, Kato M, et al. PI3-kinase and MAP-kinase signaling cascades in AILIM/ICOS- and CD28-costimulated T-cells have distinct functions between cell proliferation and IL-10 production. Biochem Biophys Res Commun 2003; 310(3): 691.
34. Witsch EJ, Peiser M, Hutloff A, et al. ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells. Eur J Immunol 2002; 32(9): 2680.
35. McAdam AJ, Greenwald RJ, Levin MA, et al. ICOS is critical for CD40-mediated antibody class switching. Nature 2001; 409(6816): 102.
36. Nanji SA, Hancock WW, Anderson CC, et al. Multiple combination therapies involving blockade of ICOS/B7RP-1 costimulation facilitate long-term islet allograft survival. Am J Transplant 2004; 4(4): 526.
37. Liu X, Bai XF, Wen J, et al. B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo. J Exp Med 200l; 194(9): 1339.
38. Sperling AI, Bluestone JA. ICOS costimulation: It's not just for TH2 cells anymore. Nat Immunol 2001; 2(7): 573.
39. Kohyama M, Sugahara D, Sugiyama S, et al. Inducible costimulator- dependent IL-10 production by regulatory T cells specific for self-antigen. Proc Natl Acad Sci USA 2004; 101(12): 4192.